GSK's Jemperli Receives FDA Approval to Treat Some Patients With Advanced Rectal Cancer

12:55 PM EDT, 10/19/2026 (MT Newswires) -- GSK's (GSK) Jemperli immunotherapy received accelerated approval from the US Food and Drug Administration to treat some patients with locally advanced rectal cancer, the FDA said in a Monday statement. This approval is expected to allow patients with mismatch repair-deficient or microsatellite instability-high tumors to avoid common treatments like chemotherapy, radiation, and surgery, according to a statement. The FDA approval was based on interim results from the company's phase 2 study, which showed that none of the patients had detectable signs of cancer after treatment, and 93% maintained cancer-free status for at least 12 months, according to the FDA. Price: 49.53, Change: +0.02, Percent Change: +0.04